4DMedical Expands Partnership with Michigan University: A New Era in Medical Innovation

Australian medtech company 4DMedical is extending its collaboration with the University of Michigan Medical Center for another three years. This partnership, valued at about $155,000, runs from July 1, 2025, to June 30, 2028. It allows the university’s clinicians and researchers access to 4DMedical’s comprehensive suite of lung analysis tools through the Enterprise Core Computing Platform.

These tools include options for CT Lung Density Analysis and Pulmonary Hypertension Analysis, along with investigational Lung Texture Analysis, pending FDA approval.

Andreas Fouras, the founder and CEO of 4DMedical, expressed excitement about this renewal, emphasizing the trust leading institutions place in their innovative solutions. He noted that this partnership reflects the real clinical value of automated lung analysis technology.

Recently, the company marked another milestone with the publication of a new multicenter trial in Respiratory Research. This study highlighted the capabilities of their X-ray Velocimetry Lung Ventilation Analysis Software (XV LVAS®). This software proved effective in detecting small airways diseases like chronic obstructive pulmonary disease (COPD), which many traditional methods often overlook.

Involving researchers from prestigious institutions such as Vanderbilt University and Johns Hopkins, the trial discovered that XV Technology provided unique insights into lung diseases, potentially allowing for better patient care while reducing reliance on invasive biopsies. Dr. Bradley Richmond from Vanderbilt noted, “We’re now able to see the invisible,” emphasizing the precision this technology offers.

To bolster its research, 4DMedical recently received AUD$1.1 million through Australia’s Economic Accelerator grant. This funding, led by the University of Adelaide and in partnership with other leading institutions, aims to develop AI-driven biomarkers to improve lung disease diagnosis and treatment.

Education minister Jason Clare praised the grant, stating it would enable world-class researchers to tackle vital healthcare challenges. Fouras mentioned that this funding will speed up R&D initiatives and expand the global reach of their technology.

As lung disease remains a significant health concern—affecting millions worldwide—4DMedical’s advancements offer hope. Recent studies show that nearly 9% of adults in the U.S. suffer from COPD, underlining the importance of innovative diagnostics in managing respiratory conditions. The collaboration between 4DMedical and the University of Michigan not only enhances research capabilities but also supports the urgent need for better diagnostic tools in healthcare.

These developments signal a promising future for lung health management, illustrating how cutting-edge technology can reshape patient outcomes.

Source link